Protease-activated receptor-2 (PAR2) mediates VEGF production through the ERK1/2 pathway in human glioblastoma cell lines  by Dutra-Oliveira, Angélica et al.
Biochemical and Biophysical Research Communications 421 (2012) 221–227Contents lists available at SciVerse ScienceDirect
Biochemical and Biophysical Research Communications
journal homepage: www.elsevier .com/locate /ybbrcProtease-activated receptor-2 (PAR2) mediates VEGF production
through the ERK1/2 pathway in human glioblastoma cell lines
Angélica Dutra-Oliveira, Robson Q. Monteiro ⇑, Andréa Mariano-Oliveira ⇑
Institute of Medical Biochemistry, Federal University of Rio de Janeiro, RJ, Brazil
a r t i c l e i n f oArticle history:
Received 16 March 2012
Available online 4 April 2012
Keywords:
Glioblastoma
Protease-activated receptor
Mitogen-activated protein kinase
Vascular endothelial growth factor
Angiogenesis0006-291X/ 2012 Elsevier Inc. Open access under the E
http://dx.doi.org/10.1016/j.bbrc.2012.03.140
⇑ Corresponding authors. Address: Instituto de B
Avenida Carlos Chagas Filho 373, Cidade Universitá
Janeiro 21941-590, Brazil. Fax: +55 212270 8647.
E-mail addresses: robsonqm@bioqmed.ufrj.br (R.Q
med.ufrj.br (A. Mariano-Oliveira).a b s t r a c t
Glioblastoma (GBM) is a highly aggressive cancer type characterized by intense neovascularization.
Several lines of evidence indicate that blood clotting enzymes play an important role in the tumor micro-
environment, mainly through the activation of protease-activated receptors (PAR). In particular, PAR1
and PAR2 isoforms may activate signal transduction pathways that promote a number of pro-tumoral
responses. However, little is known concerning the role of PAR1/PAR2 in GBM progression. In this study,
we investigated the expression and function of PAR1 and PAR2 in the human GBM cell lines A172 and
U87-MG. We also evaluated the effect of agonist peptides for PAR1 (PAR1-AP) and PAR2 (PAR2-AP) on
signaling pathways and the expression of vascular endothelial growth factor (VEGF). Immunoblotting
assays showed that A172 and U87-MG constitutively express PAR1 and PAR2. Treatment of GBM cells
with PAR1-AP or PAR2-AP enhanced Akt (protein kinase B) and extracellular signal-regulated kinase 1/
2 (ERK1/2) phosphorylation in a time-dependent manner. LY29042 and PD98059, inhibitors of the
phosphatidylinositol 3-kinase (PI3 K) and mitogen-activated protein kinase (MAPK) pathways, decreased
PAR-mediated activation of Akt and ERK1/2, respectively. In addition, we observed that PAR2, but not
PAR1, activation increased VEGF secretion in U87-MG and A172 cells. Notably, only PD98059 reduced
PAR2-mediated VEGF production by GBM cells. Our results suggest that PAR2 modulates VEGF produc-
tion through the MAPK/ERK1/2 pathway, and not the PI3 K/Akt pathway, in human GBM cell lines. There-
fore, the PAR2/MAPK signaling axis might be regarded as a relevant target for adjuvant treatment of GBM
with a possible impact on tumor angiogenesis.
 2012 Elsevier Inc. Open access under the Elsevier OA license.1. Introduction
There is a close link between the activation of blood coagulation
and cancer [1]. Blood clotting proteins are thought to play an
important role in the tumor microenvironment by facilitating
tumor growth, invasion and metastasis [2,3]. Certain proteases
may affect cellular functions by activating G protein-coupled
receptors known as protease-activated receptors (PARs) [4]. PARs
comprise a family of receptors (PAR1, PAR2, PAR3 and PAR4) that
are uniquely activated by the proteolytic cleavage of their extracel-
lular portion. This cleavage unmasks a new N-terminus, which
serves as a tethered ligand that binds to the second extracellular
domain of the protein, resulting in a variety of cellular responses
[5]. PAR1 can be cleaved and activated by thrombin and factor
Xa (FXa) as well as by plasmin, activated protein C and MMP1.
PAR2 can be activated by FVIIa, FXa, tryptase and trypsin, but notlsevier OA license. 
ioquímica Médica/CCS/UFRJ,
ria, Ilha do Fundão, Rio de
. Monteiro), amariano@bioqthrombin. Experimentally, PARs can also be activated by synthetic
peptides that mimic the neo-amino terminus of the cleaved recep-
tor [5]. Such agonist peptides are useful for the study of PARs with-
out using proteases that also have biological effects unrelated to
PAR activation. Once activated, PARs can elicit a variety of cellular
responses through multiple signaling cascade pathways [6].
PAR1 has been shown to be overexpressed in various human
cancer types including breast [7], melanoma [2], colon [8], prostate
[9], ovarian [10], esophagus [11], aggressive leukemias [12] and
others. Moreover, studies using cultured cells have demonstrated
a strong correlation between PAR1 expression and aggressive tu-
mor behavior [2,7,13]. PAR1 has been associated with several
pro-tumoral responses, including primary growth, invasion,
metastasis and angiogenesis [2,7,13].
As seen with PAR1, PAR2 is overexpressed in a number of tumor
types including pancreatic and breast cancers [14,15]. PAR2 activa-
tion has been correlated with invasion, primary tumor growth and
angiogenesis [16,17]. Notably, a gene expression study of the
human breast tumor cell line MDA-MB-231 showed that many of
the PAR2-regulated genes are also regulated by a PAR1 agonist
peptide. This suggests extensive redundancy between PAR2- and
PAR1-mediated signaling in tumor cells [18]. Accordingly, PAR1
A172 U87-MG
PAR1 (66 kDa)
PAR2 (55 kDa)
Actin (42 kDa)
Fig. 1. A172 and U87-MG cells constitutively express PAR1 and PAR2. Tumor cells
were serum-starved overnight. Then, the total levels of PAR1, PAR2 and actin were
determined by immunoblotting as described in the materials and methods section.
Proteins were quantiﬁed by densitometry using Scion Image. The data are shown as
the mean ± SD of three independent experiments.
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dant signaling pathways, including Ca2+ mobilization and activa-
tion of the mitogen-activated protein kinase (MAPK) pathway
[16,19,20].
Malignant gliomas are the most common primary brain tumors
in adults. Glioblastoma [GBM; World Health Organization (WHO)
grade IV] is the highest grade astrocytoma and is characterized
by rapid cell proliferation and a marked propensity to invade and
damage surrounding tissues [21]. In addition, intense angiogenesis
is a distinguishing pathological hallmark of GBM relative to lower-
grade gliomas. More recently, tumoral intravascular thrombosis
was reported as an additional distinction between GBM and lower
grade astrocytomas [22]. In fact, the prothrombotic properties of
GBM cell lines have been correlated with the expression of the
clotting initiator protein, tissue factor (TF) and surface exposure
of the procoagulant lipid phosphatydilserine (PS) [23,24]. As a
result, the GBM microenvironment is prone to the generation of
PAR-activating enzymes.
In this study we investigated the expression of PAR1 and PAR2
in the human GBM cell lines U87-MG and A172. In addition, we
analyzed the effect of speciﬁc agonist peptides of PAR1 and PAR2
on signaling pathways and VEGF production. Our results show that
PAR1 and PAR2 agonists promote signiﬁcant cell activation
through ERK1/2 and Akt phosphorylation. However, PAR2, but
not PAR1, activation increases VEGF production in both cell lines
mediated by MAPK pathways. Altogether, PAR2 may play a rele-
vant role in GBM angiogenesis and could be a possible target for
adjuvant therapy of this aggressive cancer type.PAR1-AP (50 µM) PAR2-AP (50 µM)
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Fig. 2. PAR1 and PAR2 induce Akt activation in GBM cell lines. (A) U87-MG and (B) A172 cells were serum-starved for 30 min and then treated with PAR1-AP (50 lM) or
PAR2-AP (50 lM) for different times. In some experiments, the cell lines were serum-starved for 30 min in the presence of LY294002 (25 lM) and then treated with PAR1-AP
(50 lM) or PAR2-AP (50 lM) for 0, 10 or 15 min at 37 C in a 5% CO2 atmosphere. The levels of total and phosphorylated Akt in the cell lysates were determined by
immunoblotting as described in the materials and methods section and quantiﬁed by densitometry using Scion Image. The data are shown as the mean ± SD of three
independent experiments. ⁄⁄P < 0.01, ⁄P < 0.05 compared with time zero in both treatments.
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2.1. Reagents
ATAP2anti-PAR1, SAM-11anti-PAR2, anti-actin, anti-phospho-ERK
1/2, anti-phospho-Akt 1/2/3, polyclonal anti-ERK 1/2and polyclonal
anti-Akt-1 antibodies were obtained from Santa Cruz Biotechnology
(SantaCruz, CA). Secondaryantibodies conjugatedwithbiotin andper-
oxidase-conjugated streptavidin were obtained from Zymed (Invitro-
gen). PAR1 agonist peptide (PAR1-AP, TFLLR-NH2) and PAR2 agonist
peptide (PAR2-AP, SLIGKL-NH2) were synthesized by Biosynthesis
Inc. (Lewisville, TX).2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-
4-one (LY294002) was obtained from Sigma (St. Louis, MO). 2-(2-dia-
mino)-3-methoxyphenyl-4H-1-benzopyran-4-one(PD98059)wasob-
tained from Calbiochem (San Diego, CA).
2.2. Cell culture
The human glioblastoma cells lines A172 and U87-MG were
maintained in Dulbecco´s Modiﬁed Eagle Medium (DMEM-F12,Gib-
coBRL) supplemented with 10% FBS (Cultilab, BR), 60 mg/L penicil-
lin, 100 mg/L streptomycin and 1.2 g/L sodium bicarbonate in
culture ﬂasks, in a 5% CO2–air mixture at 37 C. Subconﬂuent cul-
tures were washed twice with PBS, and cells were detached with
Hank’s solution containing 10 mM HEPES and 0.2 mM EDTA. Cells
were seeded at 2  105 cells/well in 12-well plates for ELISA or at
5  105 cells/well in 6-well plates for western blotting assays.
2.3. Western blot analysis of signal transduction pathways induced by
stimulation with the agonist peptides PAR1-AP or PAR2-AP
A172 and U87-MG cells were seeded at 5 105 cells/well in
6-well plates. For the quantitative analysis of PAR1 and PAR2, cellsPAR1-AP (50 µM)
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Fig. 2 (contwere washed with phosphate-buffered saline and lysed in cold buffer
containing a phosphatase inhibitor cocktail. The relative levels of PAR1
and PAR2 were expressed as a ratio to actin. The levels of the down-
stream products of two major signal transduction pathways in PAR
activation were examined. These were phospho-Akt in the PI3 K/Akt
pathway and phospho-ERK 1/2 in the MAPK/ERK pathway. Brieﬂy,
cellswerekept inDMEM-F12 in theabsenceof FBS for30 minand then
treated with PAR1-AP or PAR2-AP (50 lM) for 10, 15, 30 or 60 min. In
some cases, cells were incubated with LY294002 or PD98059 for 1 h
prior to the addition of PAR1-AP or PAR2-AP. The relative levels of
phospho-Akt and -ERK1/2 were expressed as a ratio to Akt and
ERK1/2, respectively. After 10 and 15min incubation periods, respec-
tively, the cells were harvested for western blot analysis. Cell lysates
(20 ll) were separated by SDS–polyacrylamide gel electrophoresis
(SDS–PAGE, 10–12%). Proteins were transferred onto polyvinylidene
ﬂuoride (PVDF) membranes (Millipore) and further blocked with
Tris-buffered saline (TBS) containing 5% BSA and 0.1% Tween 20 for
1 h at room temperature; the membranes were then probed with
primary antibodies overnight at 4 C. The membranes were washed
three timeswith TBS/Tweenbefore the addition of secondary antibody
for 1 h at room temperature. The membranes were further washed
and probed with peroxidase-conjugated streptavidin for 1 h at room
temperature. Immunodetection was carried out by a chemilumines-
centmethodusing theWestern Lightning ECL kit (AmershamPharma-
cia Biotech). The blots were quantiﬁed by Scion Image software.2.4. Immunoassay for the quantitation of VEGF
Cells were serum-starved for 30 min prior to stimulation with
PAR1-AP or PAR2-AP for 24 h at 37 C. VEGF protein secretion into
the cell supernatants was measured using a human VEGF ELISA kit
from Pepro Tech Inc. (Rocky Hill, NJ) according to the manufac-
turer’s instructions. In some cases, cells were incubated withPAR2-AP (50 µM)
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with agonist peptides.
2.5. Statistical analysis
All statistical analyses were performed using GraphPad Prism 5
(GraphPad Software). Two-way analysis of variance (ANOVA) com-
plemented by the Bonferroni post hoc test was used for pairwise
comparisons between test groups. Differences were considered
signiﬁcant when P < 0.05.
3. Results
3.1. A172 and U87-MG constitutively express PAR1 and PAR2
Several studies have demonstrated that PAR1 and PAR2 are con-
stitutively expressed by a variety of tumor cell types. Thus, we
investigated the expression of PAR1 and PAR2 in the human GBM
cell lines A172 and U87-MG. Western blotting assays (Fig. 1) show
that both cell lines constitutively express PAR1 and PAR2. In addi-
tion, the expression levels of these receptors were similar in both
cell lines.PAR1-AP (50 µM)
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Fig. 3. PAR1 and PAR2 mediate ERK 1/2 activation in GBM cell lines. (A) U87-MG and (B) A
PAR2-AP (50 lM) for different lengths of time. In another set of experiments, cell lines w
with PAR1-AP (50 lM) or PAR2-AP (50 lM) for 0, 10 or 15 min at 37 C in a 5% CO2 at
determined by immunoblotting as described in the materials and methods section and qu
three independent experiments. ⁄⁄⁄P < 0.001, ⁄⁄P < 0.01, ⁄P < 0.05 compared with time ze3.2. PAR1 and PAR2 induce Akt activation in GBM cells
The PI3 K/Akt signaling pathway has been suggested to be a ma-
jor determinant for poor prognosis in high-grade gliomas [25].
Therefore, we evaluated the effect of PAR activation on Akt signal-
ing in GBM cell lines. Fig. 2 shows that PAR1-AP and PAR2-AP both
induced an increase in Akt phosphorylation in the U87-MG
(Fig. 2A) and A172 (Fig. 2B) cell lines, demonstrating that both
PAR1 and PAR2 mediate the activation of the PI3 K signaling path-
way. In order to conﬁrm this hypothesis, we used LY294002, a
known PI3 K inhibitor. Fig. 2 shows that LY294002 efﬁciently
inhibited PAR1-AP- and PAR2-AP-induced Akt phosphorylation in
both cell lines.
3.3. PAR1 and PAR2 mediate ERK1/2 activation in GBM cell lines
PAR1 and PAR2 have been implicated in a number of tumor cell
responses to a variety of extracellular proteases in the tumormicro-
environment.We further investigatedwhether PAR1 and PAR2 acti-
vate ERK 1/2 in GBM cell lines by exposing U87-MG and A172 cells
to PAR1 or PAR2 agonist peptides (PAR1-AP and PAR2-AP, respec-
tively). Both agonists triggered ERK1/2 phosphorylation in thep-Erk 1/2 (42/44 kDa)
Erk 1/2 (42/44 kDa)
R2- AP (50 µM)
         15         30        60       min
U87-MG
  15     0      10     15       min
+      +        +  PD98059
p-Erk1/2 (42/44kDa)
Erk1/2 (42/44kDa) 
-
2-AP (50 µM) 
172 cells were serum-starved for 30 min and then treated with PAR1-AP (50 lM) or
ere serum-starved for 30 min in the presence of PD98059 (20 lM) and then treated
mosphere. The levels of total and phosphorylated ERK 1/2 in the cell lysates were
antiﬁed by densitometry using Scion Image. The data are shown as the mean ± SD of
ro in both treatments.
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fashion. To conﬁrm the inhibitor effects (PD98059) on ERK1/2 phos-
phorylation induced by PAR1 and PAR2 activation, the cells were
treated with the inhibitor. Fig. 3 shows that, as expected, both
PAR1-AP- and PAR2-AP-induced ERK 1/2 phosphorylation was
inhibited upon treatment with PD98059, a known MAPK pathway
inhibitor, in both cell lines. Remarkably, the effect of PD98059 on
ERK 1/2 phosphorylation was greater in cells treated with PAR2-
AP. These results demonstrate that both PAR1 and PAR2 activation
induce ERK 1/2 activation, thus promoting signaling through MAPK
pathways.3.4. PAR2 activation induces VEGF expression in GBM cell lines
GBM is one of the most highly vascularized malignant tumors
and there is strong evidence that VEGF plays a key role in this
process [26]. Furthermore, PAR1 and PAR2 have been implicated
in VEGF production by tumor cells [27]. To determine the effect
of PAR1 and PAR2 activation on VEGF production by GBM cell lines,
U87-MG and A172 cells were treated with agonist peptides, and
VEGF was quantiﬁed in the cell-conditioned medium. As
demonstrated in Fig. 4, PAR2, but not PAR1, activation increased
VEGF production in U87-MG (1.8-fold increase) and A172 (0.7-fold
increase) cells. We also evaluated whether the PI3 K pathway was0      10      15       0      10      15 0      10   
B
PAR1-AP (50 µM)
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Fig. 3 (continvolved in PAR2-induced VEGF production by GBM cells. VEGF
production by A172 cells was not affected by treatment with
LY294002 (Fig. 4B). However, treatment with LY294002 produced
a signiﬁcant increase in VEGF production in U87-MG cells stimu-
lated by either PAR1-AP or PAR2-AP (Fig. 4A). We also evaluated
whether the MAPK pathway was involved in PAR2-induced VEGF
production by GBM cells. PAR2-induced VEGF protein secretion
was signiﬁcantly decreased by the pretreatment of U87-MG
(Fig. 4A) and A172 (Fig 4B) cells with PD98059. Taken together,
these data strongly suggest that the ERK1/2 signaling pathway is
involved in PAR2-induced VEGF production.4. Discussion
Protease-activated receptors (PARs) are G protein-coupled
receptors that signal in response to a variety of extracellular
proteases. These receptors play crucial roles in hemostasis and
thrombosis, as well as inﬂammation and vascular development
[4]. Several lines of evidence have implicated PARs in tumor pro-
gression. In particular, PAR1 and PAR2 are overexpressed in several
cancer types and have been associated with tumor growth, inva-
sion, metastasis and other pro-tumoral responses. In the present
study, we evaluated the expression and function of PAR1 and
PAR2 in the human GBM cell lines U87-MG and A172. Our data   15       0       10     15      min
PD98059
p-Erk1/2 (42/44 kDa)
Erk1/2 (42/44 kDa)
p-Erk 1/2 (42/44 kDa)
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2-AP (50 µM)
       15        30       60        min
A172
+        +       +     -
R2-AP (50 µM) 
inued)
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Activation of either PAR1 or PAR2 activated signaling pathways
involving Akt and ERK 1/2. Notably, PAR2, but not PAR1, increased
VEGF production through the MAPK/ERK 1/2 pathways.
Intense angiogenesis is a distinguishing pathological hallmark
of GBM relative to lower-grade gliomas. GBM is among the most
highly vascularized malignant tumors and there is strong evi-
dence that VEGF plays a key role in this process [26]. Studies
using genetically modiﬁed mice have consistently demonstrated
that PAR2 deﬁciency delays tumor development and the angio-
genic process in a mouse breast cancer model [28]. Furthermore,
the exogenous TF/FVIIa complex inhibitor, Ixolaris, reduces
in vivo tumor angiogenesis in a human GBM model [24], possibly
through the suppression of PAR2 signaling. Those observations
support a proangiogenic role for PAR2 and coincide with our
observation that PAR2 activation increases VEGF production by
GBM cells in vitro.A172
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Fig. 4. PAR2 activation induces VEGF expression in GBM cell lines. (A) U87-MG and (B)
serum-free condition, at 37 C in a 5% CO2 atmosphere. In some cases, cells were incub
agonist peptides. VEGF secretion into the cell supernatants was quantiﬁed as described i
independent experiments. ⁄P < 0.05 compared with the treatment group.Recent studies have shown that PAR2 mediates proliferation,
migration and invasion of malignant glioma cells through the
ERK signaling pathway [29]. Notably, PAR2 activation in glioma
cells seems to be driven essentially by FVIIa/TF complex-mediated
cleavage because silencing of TF interrupts the activation of the
ERK pathway in tumor cells. The involvement of the ERK 1/2
pathway in VEGF production has been demonstrated in ﬁbroblasts,
consistent with a hypoxia-independent route for VEGF production
[30]. Furthermore, activation of ERK 1/2 has been directly
associated with PAR2 signaling that increases VEGF production
by human breast cancer cells [27]. Our data show that PAR2 activa-
tion drives VEGF production through the MAPK/ERK 1/2 pathway.
This conclusion was demonstrated by the inhibition of tumor cell
VEGF production by treatment with PD98059 prior to stimulation
with PAR2 agonist peptide.
The occurrence of intra-tumoral thrombosis in GBM has been
shown to be a distinct feature of GBM in relation to lower-gradeP 
)
PAR-2 AP 
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A172 cell lines were treated with PAR1-AP (50 lM) or PAR2-AP (50 lM) for 24 h, in
ated with LY294002 (25 lM) or PD98059 (20 lM) for 6 h prior to treatment with
n the materials and methods section. The data are shown as the mean ± SD of three
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contributes to the establishment of hypoxic areas that in turn stim-
ulate the production of pro-tumoral factors such as VEGF and IL-8
[31]. Interestingly, hypoxia upregulates TF [32] and PAR1 [33]
expression in tumor cells, thus contributing to the remodeling of
the tumor microenvironment. It remains to be determined
whether hypoxia can modulate PAR2 expression in GBM, which
could possibly synergize to promote the development of tumor
vessels.
The aberrant activation of the PI3K/Akt signaling pathway has
been described in high-grade gliomas and has been correlated with
poor prognosis in GBM [25,34]. A number of studies have
correlated Akt activation with the treatment of tumor cells with
coagulation proteases [35,36]. In addition, suppression of PAR1 sig-
naling suppresses Akt signaling in breast cancer cells [37]. In this
study, we observed that both the PAR1 and PAR2 activating pep-
tides induce Akt activation in GBM cell lines. It remains to be deter-
mined whether PAR1 and/or PAR2 modulate cell survival in GBM
models.
Considering that the GBM microenvironment is prone to gener-
ating PAR-activating enzymes, it is possible to speculate that a
blockade of coagulation activation may affect GBM progression
[38]. We recently demonstrated that pharmacological inhibition
of the TF/FVIIa complex decreases primary tumor growth in a
mouse xenograft model using U87-MG cells [24]. Moreover, Hua
and colleagues showed that the speciﬁc thrombin inhibitor arg-
atroban can reduce the in vivo growth of rat glioblastoma, although
only a modest survival improvement was shown [39]. Taken to-
gether, our results suggest that PAR1 and PAR2 may contribute
to GBM progression. Furthermore, the PAR2/MAPK signaling axis
might be regarded as a relevant target for adjuvant treatment of
GBM with a possible impact on tumor angiogenesis.
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